CNRS EMR9002 Integrative Structural Biology, Lille F-59000, France.
Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Risk Factors and Molecular Determinants of Aging-Related Diseases, Lille F-59000, France.
Biochemistry. 2023 Jun 6;62(11):1631-1642. doi: 10.1021/acs.biochem.2c00717. Epub 2023 May 11.
An increase in phosphorylation of the Tau protein is associated with Alzheimer's disease (AD) progression through unclear molecular mechanisms. In general, phosphorylation modifies the interaction of intrinsically disordered proteins, such as Tau, with other proteins; however, elucidating the structural basis of this regulation mechanism remains challenging. The bridging integrator-1 gene is an AD genetic determinant whose gene product, BIN1, directly interacts with Tau. The proline-rich motif recognized within a Tau(210-240) peptide by the SH3 domain of BIN1 (BIN1 SH3) is defined as PTPP, and this interaction is modulated by phosphorylation. Phosphorylation of T217 within the Tau(210-240) peptide led to a 6-fold reduction in the affinity, while single phosphorylation at either T212, T231, or S235 had no effect on the interaction. Nonetheless, combined phosphorylation of T231 and S235 led to a 3-fold reduction in the affinity, although these phosphorylations are not within the BIN1 SH3-bound region of the Tau peptide. Using nuclear magnetic resonance (NMR) spectroscopy, these phosphorylations were shown to affect the local secondary structure and dynamics of the Tau(210-240) peptide. Models of the (un)phosphorylated peptides were obtained from molecular dynamics (MD) simulation validated by experimental data and showed compaction of the phosphorylated peptide due to increased salt bridge formation. This dynamic folding might indirectly impact the BIN1 SH3 binding by a decreased accessibility of the binding site. Regulation of the binding might thus not only be due to local electrostatic or steric effects from phosphorylation but also to the modification of the conformational properties of Tau.
Tau 蛋白磷酸化的增加与阿尔茨海默病(AD)的进展有关,但其分子机制尚不清楚。一般来说,磷酸化修饰了内在无序蛋白(如 Tau)与其他蛋白的相互作用;然而,阐明这种调控机制的结构基础仍然具有挑战性。桥连整合蛋白 1 基因(BIN1)是 AD 的遗传决定因素,其产物 BIN1 直接与 Tau 相互作用。BIN1 SH3 结构域识别 Tau(210-240)肽中的富含脯氨酸基序,该基序被定义为 PTPP,且这种相互作用受磷酸化调节。Tau(210-240)肽中 T217 的磷酸化导致亲和力降低 6 倍,而 T212、T231 或 S235 单一磷酸化对相互作用没有影响。然而,T231 和 S235 的组合磷酸化导致亲和力降低 3 倍,尽管这些磷酸化不在 Tau 肽的 BIN1 SH3 结合区域内。使用核磁共振(NMR)光谱学,这些磷酸化作用被证明会影响 Tau(210-240)肽的局部二级结构和动力学。通过实验数据验证的分子动力学(MD)模拟获得了(未)磷酸化肽的模型,结果显示由于增加了盐桥形成,磷酸化肽的结构更加紧凑。这种动态折叠可能会通过降低结合位点的可及性,间接地影响 BIN1 SH3 的结合。因此,结合的调节不仅可能是由于磷酸化的局部静电或空间效应,还可能是由于 Tau 构象特性的改变。